Evidence map›Paper›PMID 34071719›Full record

ArticleGenes2021

Health Characteristics of Patients with Cystic Fibrosis whose Genotype Includes a Variant of the Nucleotide Sequence c.3140-16T>A and Functional Analysis of this Variant.

Elena Kondratyeva, Tatyana Bukharova, Anna Efremova, Yuliya Melyanovskaya, Natalia Bulatenko, Ksenia Davydenko, Alexandra Filatova, Mikhail Skoblov, Stanislav Krasovsky, Nika Petrova and 10 more

Open access · goldAbstract read
In one paragraph

Article in Genes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. A novelHeliyon · 2024
    Article
  3. Comprehensive Assessment ofInternational journal of molecular sciences · 2024
    Article
  4. Article
  5. Article
  6. Clinical and Functional Characteristics of the E92KInternational journal of molecular sciences · 2023
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 1 institution in 1 country.

Elena KondratyevaResearch Centre for Medical Genetics, 115522 Moscow, Russia.ORCID 0000-0001-6395-0407
Tatyana BukharovaResearch Centre for Medical Genetics, 115522 Moscow, Russia.ORCID 0000-0003-0481-256X
Anna EfremovaResearch Centre for Medical Genetics, 115522 Moscow, Russia.
Yuliya MelyanovskayaResearch Centre for Medical Genetics, 115522 Moscow, Russia.ORCID 0000-0002-8814-5532
Natalia BulatenkoResearch Centre for Medical Genetics, 115522 Moscow, Russia.
Ksenia DavydenkoResearch Centre for Medical Genetics, 115522 Moscow, Russia.ORCID 0000-0001-7620-9175
Alexandra FilatovaResearch Centre for Medical Genetics, 115522 Moscow, Russia.ORCID 0000-0002-5979-0727
Mikhail SkoblovResearch Centre for Medical Genetics, 115522 Moscow, Russia.ORCID 0000-0002-7293-3438
Stanislav KrasovskyResearch Centre for Medical Genetics, 115522 Moscow, Russia.
Nika PetrovaResearch Centre for Medical Genetics, 115522 Moscow, Russia.
Alexander PolyakovResearch Centre for Medical Genetics, 115522 Moscow, Russia.
Tagui AdyanResearch Centre for Medical Genetics, 115522 Moscow, Russia.
Elena AmelinaResearch Centre for Medical Genetics, 115522 Moscow, Russia.
Vera ShadrinaFaculty of Pediatrics, Perm State Medical University, 614990 Perm, Russia.ORCID 0000-0002-2588-2260
Elena ZhekaiteResearch Centre for Medical Genetics, 115522 Moscow, Russia.
Aysa ZodbinovaResearch Centre for Medical Genetics, 115522 Moscow, Russia.
Alexander ChernyakResearch Centre for Medical Genetics, 115522 Moscow, Russia.ORCID 0000-0002-2001-5504
Rena ZinchenkoResearch Centre for Medical Genetics, 115522 Moscow, Russia.ORCID 0000-0003-3586-3458
Sergei KutsevResearch Centre for Medical Genetics, 115522 Moscow, Russia.
Dmitry GoldshteinResearch Centre for Medical Genetics, 115522 Moscow, Russia.
Research Centre for Medical Genetics · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cystic fibrosis (CF) is the most common monogenic autosomal recessive disease, associated with pathogenic variants in the CFTR gene. The splicing variant c.3140-16T>A (3272-16T>A) has been described previously and, according to the Russian CF Patients Registry, occurs with a frequency of 0.34%. The phenotypic features of CF patients with the c.3140-16T>A variant were compared with those of patients with the genotype F508del/F508del. Patients with the allele c.3140-16T>A had higher average age and age at diagnosis, and the allele was present in a greater proportion of adults. Patients carrying the c.3140-16T>A allele were characterised by better physical development indicators, both in adults and in children, had preserved pancreatic function, as well as the absence of a number of complications, and required pancreatic enzyme replacement therapy less often than patients with the F508del/F508del genotype. Sweat test values also were lower in patients with the c.3140-16T>A genotype. According to the results of clinical and laboratory studies, the phenotype of patients with the genetic variant c.3140-16T>A can be considered "mild". Functional CFTR protein activity in the presence of c.3140-16T>A was evaluated using intestinal current measurements (ICM) and the forskolin-induced swelling assay on organoids obtained from patients' rectal biopsies. c.3140-16T>A had high residual CFTR channel activity and was amenable to effective pharmacological correction with thea VX-770 potentiator. To evaluate the effect of the variant on CFTR pre-mRNA splicing we performed a minigene assay, as well as RT-PCR analysis of RNA isolated from the nasal epithelium and rectal biopsy of patients. We showed that the c.3140-16T>A variant creates a novel acceptor AG dinucleotide within CFTR intron 19, resulting in a 14-nucleotide extension of exon 20. This frameshift produces a premature termination codon and triggers mRNA degradation by the nonsense-mediated decay (NMD) mechanism. Moreover, we observed that the c.3140-16T>A allele could produce a residual amount of normally spliced transcript, thus explaining the patient's mild phenotype.

Indexed as

GenotypePhenotypeAdolescentAdultCells, CulturedChildCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorFemaleFrameshift MutationHumansMaleNasal MucosaNonsense Mediated mRNA DecayOrganoidsSweatCFTR protein, humanCystic Fibrosis Transmembrane Conductance Regulatorc.3140-16T>A variantCFTRcystic fibrosis

Identifiers

PMID34071719
PMCPMC8229552
OpenAlexW3164956421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.